Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant autogene cevumeran plus atezolizumab and mFOLFIRINOX versus mFOLFIRINOX alone after resection of pancreatic ductal adenocarcinoma
2022-502404-73-00Phase 2Authorised
- Sponsor
- Genentech
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Autogene cevumeran + atezolizumab + mFOLFIRINOX with mFOLFIRINOX alone (2 arms). Primary endpoint: Disease-free survival after randomization. Planned start Jun 2024; status: authorised.
02
Drugs
autogene cevumeranatezolizumabmFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2022-502404-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502404-73-00.